CoChat

New-Onset Diabetes After Renal Transplantation

Open access
Ghisdal, Lidia, Van Laecke, Steven, Abramowicz, Marc J., Vanholder, Raymond, Abramowicz, Daniel · 2012 · Diabetes Care
Cited by 128

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

New-onset diabetes after transplantation (NODAT) is a serious and frequent metabolic complication after renal transplantation. This entity is currently well defined since the publication of the International Consensus Guidelines in 2003. Here, we review the factors contributing to the risk of NODAT and the strategies related to modifiable factors, with emphasis on practical issues. Recognizing these factors may help clinicians to evaluate prospectively appropriate prevention strategies to minimize the risk of NODAT. Over the past 50 years, the concept of NODAT has evolved in terms of name and definition. Before 2003, de novo diabetes that developed after transplantation was described in various terms, most frequently “posttransplantation diabetes mellitus,” and suffered from a lack of consensus regarding its definition. The most commonly used clinical definition was the requirement of insulin for a minimum period posttransplantation (often 30 days). This definition, however, identified only the most severe cases, leaving out the majority of patients with glucose metabolism disorders. International Consensus Guidelines on NODAT were published in 2003. They recommended that the diagnosis of NODAT should be based on the American Diabetes Association (ADA) criteria for type 2 diabetes published in 2003 (1,2). Since then, a follow-up report from the International Expert Committee further lowered the inferior limit of fasting plasma glucose (FPG) (100 mg/dL) that corresponds to impaired fasting glucose (IFG), based on epidemiologic predictive data (3). In addition, since 2009, the International Expert Committee recommended the use of a standardized A1C assay for diabetes diagnosis (A1C level ≥6.5%), a position that has been endorsed by ADA in 2010 (4). The Expert Committee stated that A1C assay cannot be used in conditions that change red cell turnover. This is the case of end-stage renal disease (ESRD) patients and newly transplanted kidney patients. For instance, the posttransplant period is frequently associated …

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-1230

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 128

Metadata

Authors
Ghisdal, L., Van Laecke, S., Abramowicz, M. J., Vanholder, R., & Abramowicz, D.
Venue
Diabetes Care
Published
2011-12-09
Volume
35
Issue
1
Pages
181-188
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2107522068
Cited by
128
References
5
FWCI
3.72
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: New-Onset Diabetes After Renal Transplantation. https://app.cochat.ai/papers/10.2337/dc11-1230
The paper
Ghisdal, L., Van Laecke, S., Abramowicz, M. J., Vanholder, R., & Abramowicz, D. (2012). New-Onset Diabetes After Renal Transplantation. Diabetes Care. https://doi.org/10.2337/dc11-1230

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.